-
Kingworld Medicines Group Issues Positive Profit Alert for 2021
PharmaSources.com
March 24, 2022
Kingworld Medicines Group Limited (stock code: 01110.HK), a leading omni-channel enterprise providing greater health products and services in China, issued today a positive profit alert as it expects to record...
-
Joint Research Shows that DENSO's Microalga, Coccomyxa sp. KJ Has Virucidal Effect against COVID-19
PharmaSources.com
March 24, 2022
Chubu University, Tokai University, Tohoku University School of Medicine and DENSO Corporation have found that monogalactosyl diacylglyceride (MGDG), a component contained in the chloroplasts of a microalga...
-
CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021
PharmaSources.com
February 24, 2022
Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021").
-
Q&M Dental records historic highest-ever revenue and profit after tax for year ended 31 December 2021 and declares a full year dividend yielding 7%
PharmaSources.com
February 24, 2022
Catalist listed Aoxin Q&M Dental Limited ("Aoxin" or "the Group"), today announced a 20.8% increase in revenue to RMB160.2 million for full year ended 31 December 2021 ("FY2021").
-
China approves use of Pfizer’s COVID drug Paxlovid
ExpressPharma
February 15, 2022
It is not immediately clear if China is already in talks with Pfizer to procure the pill.
-
G-NiiB probiotics - world's first microbiome-based immunity formulas now available at IMI
prnasia
February 15, 2022
IMI - Integrated Medicine Institute, Asia's largest natural health clinic, is pleased to announce the availability of G-NiiB Immunity Pro and G-NiiB Immunity Plus probiotic formulas designed to tackle gut bacterial imbalances...
-
FDA grants EUA to Lilly’s bebtelovimab for Covid-19 treatment
Pharmaceutical-Technology
February 15, 2022
Bebtelovimab is indicated for treating mild-to-moderate Covid-19 in adults and paediatric patients aged 12 years and above.
-
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
WorldPharmaNews
February 15, 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification.
-
Coalition formed to tackle ‘hidden pandemic’ of antibiotic resistant infections
EuropeanPharmaceuticalReview
February 14, 2022
A White Paper launched by a coalition of partners spanning pharmaceuticals, MedTech and diagnostics, calls for a transformational change in the way infection is detected, monitored...
-
Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients
prnasia
February 14, 2022
Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics...